Comparative effect of ciprofloxacin and moxifloxacin on the modulation of bile acid profiles and gut microbiota in rats
DOI:
https://doi.org/10.1590/s2175-97902022e191086%20Keywords:
Ciprofloxacin, Moxifloxacin, Bile acids, Hydrophobicity index, Gut microbiotaAbstract
Fluoroquinolones are an important class of antimicrobial agents to manage infectious diseases. However, knowledge about how host bile acids are modified by fluoroquinolones is limited. We investigated and compared the impact of fluoroquinolones on circulating bile acid profiles and gut microbiota from in vivo studies. We administered ciprofloxacin (100 mg/kg/day) or moxifloxacin (40 mg/kg/day) orally to male Wistar rats for seven days. Fifteen bile acids (BAs) from the serum and large intestine were quantified by HPLC-MS/MS. The diversity of gut microbiota after ciprofloxacin and moxifloxacin treatment was analyzed using high-throughput, next-generation sequencing technology. The two fluoroquinolone-treated groups had different BA profiles. Ciprofloxacin significantly reduced the hydrophobicity index of the BA pool, reduced secondary BAs, and increased taurine-conjugated primary BAs in both the serum and large intestine as compared with moxifloxacin. Besides, ciprofloxacin treatment altered intestinal microbiota with a remarkable increase in Firmicutes to Bacteroidetes ratio, while moxifloxacin exerted no effect. What we found suggests that different fluoroquinolones have a distinct effect on the host BAs metabolism and intestinal bacteria, and therefore provide guidance on the selection of fluoroquinolones to treat infectious diseases.
Downloads
References
Alkhedaide AQ, Ismail TA, Alotaibi SH, Nassan MA, Shehri ZSA. Preventive effect of artemisinin extract against cholestasis induced via lithocholic acid exposure. Biosci Rep. 2018;38 pii: BSR20181011.
Antunes LC, Han J, Ferreira RB, Lolić P, Borchers CH, Finlay BB. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother. 2011;55(4):1494-1503.
Aspinall SL, Good CB, Jiang R, McCarren M, Dong D and Cunningham FE. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis. 2009;49(3):402-408.
Carneiro EM, Latorraca MQ, Araujo E, Beltrá M, Oliveras MJ, Navarro M, et al. Taurine supplementation modulates glucose homeostasis and islet function. J Nutr Biochem. 2009;20:503-511.
Chiang JYL, Ferrell JM. Bile acid metabolism in liver pathobiology. Gene Expr. 2018;18(2):71-87.
Chiang JYL. Bile acids: regulation of synthesis. J Lipid Res. 2009;50:1955-1966.
Chou HW, Wang JL, Chang CH, Lee JJ, Shau WY, Lai MS. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis . 2013;57(7):971-980.
Cipriani S, Mencarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, Fiorucci S. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One. 2011;6(10):e25637.
Dong W, Liu L, Dou Y, Xu M, Liu T, Wang S, et al. Deoxycholic acid activates epidermal growth factor receptor and promotes intestinal carcinogenesis by ADAM17-dependent ligand release. J Cell Mol Med. 2018;22(9):4263-4273.
Ghaly H, Kriete C, Sahin S, Pflöger A, Holzgrabe U, Zünkler BJ, et al. The insulinotropic effect of fluoroquinolones. Biochem Pharmacol. 2009;77(6):1040-1052.
Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes. 2013;62(12):4184-4191.
Hashimoto S, Igimi H, Uchida K, Satoh T, Benno Y, Takeuchi N. Effects of beta-lactam antibiotics on intestinal microflora and bile acid metabolism in rats. Lipids. 1996;31(6):601-609.
He D, Barnes S, Falany CN. Rat liver bile acid CoA: amino acid N-acyltransferase: expression, characterization, and peroxisomal localization. J Lipid Res . 2003;44(12):2242-2249.
Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res . 1989;30(5):719-730.
Jeevanandam M, Ramias L, Schiller WR. Altered plasma free amino acid levels in obese traumatized man. Metabolism. 1991;40(4):385-390.
Kundu S, Kumar S, Bajaj A. Cross-talk between bile acids and gastrointestinal tract for progression and development of cancer and its therapeutic implications. IUBMB Life. 2015;67(7):514-523.
Ley RE, Hamady M, Lozupone C, Turnbaugh PJ, Ramey RR, Bircher JS, et al. Evolution of mammals and their gut microbes. Science. 2008;320(5883):1647-1651.
Li Y, Hafey MJ, Duong H, Evers R, Cheon K, Holder DJ, et al. Antibiotic-induced elevations of plasma bile acids in rats independent of Bsep inhibition. Toxicol Sci. 2017;157(1):30-40.
Lucangioli SE, Castaño G, Contin MD, Tripodi VP. Lithocholic acid as a biomarker of intrahepatic cholestasis of pregnancy during ursodeoxycholic acid treatment. Ann Clin Biochem. 2009;46(Pt 1):44-49.
Miyata M, Hayashi K, Yamakawa H, Yamazoe Y, Yoshinari K. Antibacterial drug treatment increases intestinal bile acid absorption via elevated levels of ileal apical sodium-dependent bile acid transporter but not organic solute transporter α protein. Biol Pharm Bull. 2015;38(3):493-496.
Ridlon JM, Kang DJ, Hylemon PB. Bile acids and the gut microbiome. Curr Opin Gastroenterol. 2014;30(3):332-338.
Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res . 2006;47(2):241-259.
Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137-174.
Sagar NM, Cree IA, Covington JA, Arasaradnam RP. The interplay of the gut microbiome, bile acids, and volatile organic compounds. Gastroenterol Res Pract. 2015;2015:398585.
Salzman NH, de Jong H, Paterson Y, Harmsen HJ, Welling GW, Bos NA. Analysis of 16S libraries of mouse gastrointestinal microflora reveals a large new group of mouse intestinal bacteria. Microbiology. 2002;148(Pt 11):3651-3660.
Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-betamuricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013;17(2):225-235.
Smith KM, Lomaestro BM. What role do fluoroquinolone antimicrobial agents play in cardiac dysfunction and altered glycemic control? J Pharm Pract. 2003;16(5):349-360
Staley C, Weingarden AR, Khoruts A, Sadowsky MJ. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol. 2017;101(1):47-64.
Tsuboyama-Kasaoka N, Shozawa C, Sano K, Kamei Y, Kasaoka S, Hosokawa Y, et al. Taurine (2-aminoethanesulfonic acid) deficiency creates a vicious circle promoting obesity. Endocrinology. 2006;147(7):3276-3284.
Yoshimoto S, Loo TM, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induce gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97-101.
Zhang Y, Limaye PB, Renaud HJ, Klaassen CD. Effect of various antibiotics on modulation of intestinal microbiota and bile acid profile in mice. Toxicol Appl Pharmacol. 2014;277(2):138-145.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
How to Cite
Funding data
-
National Natural Science Foundation of China
Grant numbers 81601098;81603181
